Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 3/2014

01.05.2014 | Original Article

A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis

verfasst von: Andrea Mignarri, Gian Nicola Gallus, Maria Teresa Dotti, Antonio Federico

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder characterized by a heterogeneous presentation and a broad spectrum of clinical manifestations. Since early diagnosis and replacement therapy with chenodeoxycholic acid can prevent clinical deterioration, our aim was to develop a diagnostic tool to identify and treat CTX patients at an initial stage of the disease.

Methods

We devised a suspicion index, composed of weighted scores assigned to indicators such as family history characteristics and common systemic and neurological features, on the basis of a pooled analysis of selected international CTX series. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index was then applied retrospectively to our CTX population.

Results

Early systemic signs such as cataract, diarrhea and neonatal cholestatic jaundice were considered strong indicators, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score ≥ 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score ≥ 200, with one very strong or four strong indicators, warranted CYP27A1 gene analysis. In our patients, age at diagnosis was 35.5 ± 11.8 years (mean ± standard deviation), whereas with the diagnostic tool it became 10.6 ± 9.8 years (p < 0.01).

Conclusions

Our suspicion index provides a simple and inexpensive diagnostic tool allowing diagnosis and treatment of CTX before neurological disability occurs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876PubMedCrossRef Barkhof F, Verrips A, Wesseling P et al (2000) Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 217:869–876PubMedCrossRef
Zurück zum Zitat Batta AK, Shefer S, Batta M, Salen G (1985) Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. J Lipid Res 26:690–698PubMed Batta AK, Shefer S, Batta M, Salen G (1985) Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis; monitoring by high performance liquid chromatography. J Lipid Res 26:690–698PubMed
Zurück zum Zitat Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649–1652PubMedCrossRef Berginer VM, Salen G, Shefer S (1984) Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 311:1649–1652PubMedCrossRef
Zurück zum Zitat Berginer VM, Shany S, Alkalay D et al (1993) Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42:69–74PubMedCrossRef Berginer VM, Shany S, Alkalay D et al (1993) Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42:69–74PubMedCrossRef
Zurück zum Zitat Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147PubMedCrossRef Berginer VM, Gross B, Morad K et al (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147PubMedCrossRef
Zurück zum Zitat Björkhem I, Hansson M (2010) Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem Biophys Res Commun 396:46–49PubMedCrossRef Björkhem I, Hansson M (2010) Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem Biophys Res Commun 396:46–49PubMedCrossRef
Zurück zum Zitat Cali JJ, Russell DW (1991) Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 266:7774–7778PubMed Cali JJ, Russell DW (1991) Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 266:7774–7778PubMed
Zurück zum Zitat Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R (2002) Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 25:501–513PubMedCrossRef Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R (2002) Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 25:501–513PubMedCrossRef
Zurück zum Zitat Cruysberg JR (2009) Children with cataract and chronic diarrhoea: cerebrotendinous xanthomatosis. J Inherit Metab Dis 32:309PubMedCrossRef Cruysberg JR (2009) Children with cataract and chronic diarrhoea: cerebrotendinous xanthomatosis. J Inherit Metab Dis 32:309PubMedCrossRef
Zurück zum Zitat Cruysberg JR, Wevers RA, Tolboom JJ (1991) Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol 112:606–607PubMed Cruysberg JR, Wevers RA, Tolboom JJ (1991) Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. Am J Ophthalmol 112:606–607PubMed
Zurück zum Zitat De Stefano N, Dotti MT, Mortilla M, Federico A (2001) Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 124:121–131PubMedCrossRef De Stefano N, Dotti MT, Mortilla M, Federico A (2001) Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 124:121–131PubMedCrossRef
Zurück zum Zitat Federico A, Dotti MT (1996) Cerebrotendinous xanthomatosis. In: Moser HW (ed) Handbook of Clinical Neurology 22:599–613 Federico A, Dotti MT (1996) Cerebrotendinous xanthomatosis. In: Moser HW (ed) Handbook of Clinical Neurology 22:599–613
Zurück zum Zitat Federico A, Dotti MT (2003) Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 18:633–638PubMedCrossRef Federico A, Dotti MT (2003) Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 18:633–638PubMedCrossRef
Zurück zum Zitat Ginanneschi F, Mignarri A, Mondelli M et al (2013) Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol 260:268–274PubMedCrossRef Ginanneschi F, Mignarri A, Mondelli M et al (2013) Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. J Neurol 260:268–274PubMedCrossRef
Zurück zum Zitat Koopman BJ, Wolthers BG, van der Molen JC, Waterreus RJ (1985) Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. Clin Chim Acta 152:115–122PubMedCrossRef Koopman BJ, Wolthers BG, van der Molen JC, Waterreus RJ (1985) Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. Clin Chim Acta 152:115–122PubMedCrossRef
Zurück zum Zitat Lee MH, Hazard S, Carpten JD et al (2001) Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 42:159–169PubMedCentralPubMed Lee MH, Hazard S, Carpten JD et al (2001) Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res 42:159–169PubMedCentralPubMed
Zurück zum Zitat Lorincz MT, Rainier S, Thomas D, Fink JK (2005) Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol 62:1459–1463PubMedCrossRef Lorincz MT, Rainier S, Thomas D, Fink JK (2005) Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. Arch Neurol 62:1459–1463PubMedCrossRef
Zurück zum Zitat Martini G, Mignarri A, Ruvio M et al (2013) Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 92:282–286PubMedCrossRef Martini G, Mignarri A, Ruvio M et al (2013) Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. Calcif Tissue Int 92:282–286PubMedCrossRef
Zurück zum Zitat Mignarri A, Rossi S, Ballerini M et al (2011) Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 258:783–790PubMedCrossRef Mignarri A, Rossi S, Ballerini M et al (2011) Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 258:783–790PubMedCrossRef
Zurück zum Zitat Mignarri A, Dotti MT, Del Puppo M et al (2012a) Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation: six-year MRI follow-up. Neuroradiology 54:649–651PubMedCrossRef Mignarri A, Dotti MT, Del Puppo M et al (2012a) Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation: six-year MRI follow-up. Neuroradiology 54:649–651PubMedCrossRef
Zurück zum Zitat Mignarri A, Falcini M, Vella A et al (2012b) Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 18:99–101PubMedCrossRef Mignarri A, Falcini M, Vella A et al (2012b) Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 18:99–101PubMedCrossRef
Zurück zum Zitat Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S (1991) Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40:741–746PubMedCrossRef Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S (1991) Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 40:741–746PubMedCrossRef
Zurück zum Zitat Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P (2008) Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis 31:S241–S245PubMedCrossRef Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P (2008) Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis 31:S241–S245PubMedCrossRef
Zurück zum Zitat Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A (2008) Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 255:839–842PubMedCrossRef Pilo de la Fuente B, Ruiz I, Lopez de Munain A, Jimenez-Escrig A (2008) Cerebrotendinous xanthomatosis: neuropathological findings. J Neurol 255:839–842PubMedCrossRef
Zurück zum Zitat Pilo de la Fuente B, Jimenez-Escrig A, Lorenzo JR et al (2011a) Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 18:1203–1211PubMedCrossRef Pilo de la Fuente B, Jimenez-Escrig A, Lorenzo JR et al (2011a) Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 18:1203–1211PubMedCrossRef
Zurück zum Zitat Pilo de la Fuente B, Sobrido MJ, Girós M et al (2011b) Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis. Neurologia 26:397–404PubMedCrossRef Pilo de la Fuente B, Sobrido MJ, Girós M et al (2011b) Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis. Neurologia 26:397–404PubMedCrossRef
Zurück zum Zitat Pilo B, de Blas G, Sobrido MJ et al (2011) Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve 43:531–536PubMedCrossRef Pilo B, de Blas G, Sobrido MJ et al (2011) Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve 43:531–536PubMedCrossRef
Zurück zum Zitat Rubio-Agusti I, Kojovic M, Edwards MJ et al (2012) Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 27:1769–1774PubMedCrossRef Rubio-Agusti I, Kojovic M, Edwards MJ et al (2012) Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 27:1769–1774PubMedCrossRef
Zurück zum Zitat Salen G, Berginer V, Shore V et al (1987) Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med 316:1233–1238PubMedCrossRef Salen G, Berginer V, Shore V et al (1987) Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. N Engl J Med 316:1233–1238PubMedCrossRef
Zurück zum Zitat Salen G, Batta AK, Tint GS, Shefer S (1994) Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism 43:1018–1022PubMedCrossRef Salen G, Batta AK, Tint GS, Shefer S (1994) Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Metabolism 43:1018–1022PubMedCrossRef
Zurück zum Zitat Samenuk P, Koffman BM (2001) Chenodeoxycholic treatment of cerebrotendinous xanthomatosis. Neurology 56:695–696PubMedCrossRef Samenuk P, Koffman BM (2001) Chenodeoxycholic treatment of cerebrotendinous xanthomatosis. Neurology 56:695–696PubMedCrossRef
Zurück zum Zitat Siman-Tov T, Meiner V, Gadoth N (2006) Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci 243:83–86PubMedCrossRef Siman-Tov T, Meiner V, Gadoth N (2006) Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? J Neurol Sci 243:83–86PubMedCrossRef
Zurück zum Zitat Su CS, Chang WN, Huang SH et al (2010) Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 25:452–458PubMedCrossRef Su CS, Chang WN, Huang SH et al (2010) Cerebrotendinous xanthomatosis patients with and without parkinsonism: clinical characteristics and neuroimaging findings. Mov Disord 25:452–458PubMedCrossRef
Zurück zum Zitat Van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316PubMedCrossRef Van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316PubMedCrossRef
Zurück zum Zitat Verrips A, Wevers RA, Van Engelen BG et al (1999) Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 48:233–238PubMedCrossRef Verrips A, Wevers RA, Van Engelen BG et al (1999) Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 48:233–238PubMedCrossRef
Zurück zum Zitat Verrips A, Hoefsloot LH, Steenbergen GC et al (2000a) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 23:908–919CrossRef Verrips A, Hoefsloot LH, Steenbergen GC et al (2000a) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 23:908–919CrossRef
Zurück zum Zitat Verrips A, van Engelen BG, Wevers RA et al (2000b) Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol 57:520–524PubMedCrossRef Verrips A, van Engelen BG, Wevers RA et al (2000b) Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol 57:520–524PubMedCrossRef
Zurück zum Zitat von Bahr S, Björkhem I, Van’t Hooft F et al (2005) Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr 40:481–486CrossRef von Bahr S, Björkhem I, Van’t Hooft F et al (2005) Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy. J Pediatr Gastroenterol Nutr 40:481–486CrossRef
Zurück zum Zitat Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic Acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83PubMedCrossRef Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic Acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83PubMedCrossRef
Metadaten
Titel
A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis
verfasst von
Andrea Mignarri
Gian Nicola Gallus
Maria Teresa Dotti
Antonio Federico
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 3/2014
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-013-9674-3

Weitere Artikel der Ausgabe 3/2014

Journal of Inherited Metabolic Disease 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.